Patents by Inventor Doris Riether

Doris Riether has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10787432
    Abstract: This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R1, R2, R3, R4, R5, R6 and R7 have meanings given in the description.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: September 29, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Doris Riether, Marco Ferrara, Niklas Heine, Uta Lessel, Janet Rachel Nicholson, Anton Pekcec
  • Publication number: 20200283418
    Abstract: The present invention relates to novel N-(2,2-difluoroehtyl)-N-[(Pyrimidinylamino)propanyl]-arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Application
    Filed: September 26, 2018
    Publication date: September 10, 2020
    Inventors: Doris RIETHER, Niklas HEINE, Uta Friederike LESSEL, Stefan SCHEUERER
  • Publication number: 20200262830
    Abstract: This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
    Type: Application
    Filed: January 22, 2020
    Publication date: August 20, 2020
    Inventors: Doris Riether, Florian Paul Christian Binder, Henri Doods, Stephan Georg Mueller, Janet Rachel Nicholson, Achim Sauer
  • Patent number: 10738031
    Abstract: This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar1 and Ar2 have meanings given in the description.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: August 11, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Doris Riether, Marco Ferrara, Niklas Heine, Uta Lessel, Janet Rachel Nicholson, Anton Pekcec
  • Publication number: 20200231575
    Abstract: The present invention relates to novel N-[(Pyrimidinylamino)propanyl]-, N-[(Pyridylamino)propanyl]- and N-[(Pyrazinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Application
    Filed: July 26, 2018
    Publication date: July 23, 2020
    Inventors: Doris RIETHER, Marco FERRARA, Niklas HEINE, Uta Friederike LESSEL, Radoslaw LIPINSKI, Stefan SCHEUERER
  • Patent number: 10710984
    Abstract: The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyridinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: July 14, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Doris Riether, Marco Ferrara, Niklas Heine, Uta Lessel, Janet Rachel Nicholson, Anton Pekcec, Stefan Scheuerer
  • Patent number: 10604511
    Abstract: This invention relates to compounds of formula I a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R1, R2 and R3 have meanings given in the description.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: March 31, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Doris Riether, Marco Ferrara, Niklas Heine, Uta Lessel, Janet Rachel Nicholson, Anton Pekcec
  • Patent number: 10570125
    Abstract: This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: February 25, 2020
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Doris Riether, Florian Paul Christian Binder, Henri Doods, Stephan Georg Mueller, Janet Rachel Nicholson, Achim Sauer
  • Patent number: 10392369
    Abstract: This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R1, R2, R3, R4, R5 have meanings given in the description.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: August 27, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Doris Riether, Marco Ferrara, Niklas Heine, Uta Lessel, Janet Rachel Nicholson, Anton Pekcec
  • Publication number: 20190161481
    Abstract: This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
    Type: Application
    Filed: September 27, 2018
    Publication date: May 30, 2019
    Inventors: Doris Riether, Florian Paul Christian Binder, Henri Doods, Stephan Georg Mueller, Janet Rachel Nicholson, Achim Sauer
  • Publication number: 20190112292
    Abstract: This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar1 and Ar2 have meanings given in the description.
    Type: Application
    Filed: April 7, 2017
    Publication date: April 18, 2019
    Inventors: Doris RIETHER, Marco FERRARA, Niklas HEINE, Uta LESSEL, Janet Rachel NICHOLSON, Anton PEKCEC
  • Publication number: 20190112296
    Abstract: This invention relates to compounds of formula (I) a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R1, R2 and R3 have meanings given in the description.
    Type: Application
    Filed: April 7, 2017
    Publication date: April 18, 2019
    Inventors: Doris RIETHER, Marco FERRARA, Niklas HEINE, Uta LESSEL, Janet Rachel NICHOLSON, Anton PEKCEC
  • Publication number: 20190112295
    Abstract: This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R1, R2, R3, R4, R5 have meanings given in the description.
    Type: Application
    Filed: April 17, 2017
    Publication date: April 18, 2019
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Doris RIETHER, Marco FERRARA, Niklas HEINE, Uta LESSEL, Janet Rachel NICHOLSON, Anton PEKCEC
  • Publication number: 20190112291
    Abstract: This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R1, R2, R3, R4, R5, R6 and R7 have meanings given in the description.
    Type: Application
    Filed: April 7, 2017
    Publication date: April 18, 2019
    Inventors: Doris RIETHER, Marco FERRARA, Niklas HEINE, Uta LESSEL, Janet Rachel NICHOLSON, Anton PEKCEC
  • Publication number: 20190112297
    Abstract: The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyridinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Application
    Filed: April 7, 2017
    Publication date: April 18, 2019
    Inventors: Doris RIETHER, Marco FERRARA, Niklas HEINE, Uta LESSEL, Janet Rachel NICHOLSON, Anton PEKCEC, Stefan SCHEUERER
  • Patent number: 10112934
    Abstract: This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: October 30, 2018
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Doris Riether, Florian Paul Christian Binder, Henri Doods, Stephan Georg Mueller, Janet Rachel Nicholson, Achim Sauer
  • Patent number: 9884854
    Abstract: The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyrazinylamino)-propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: February 6, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Doris Riether, Marco Ferrara, Niklas Heine, Uta Friederike Lessel, Janet Rachel Nicholson, Anton Pekcec, Stefan Scheuerer
  • Publication number: 20170320868
    Abstract: This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
    Type: Application
    Filed: April 19, 2017
    Publication date: November 9, 2017
    Inventors: Doris Riether, Florian Paul Christian Binder, Henri Doods, Stephan Georg Mueller, Janet Rachel Nicholson, Achim Sauer
  • Publication number: 20170298053
    Abstract: The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyrazinylamino)-propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Application
    Filed: April 12, 2017
    Publication date: October 19, 2017
    Inventors: Doris RIETHER, Marco FERRARA, Niklas HEINE, Uta Friederike LESSEL, Janet Rachel NICHOLSON, Anton PEKCEC, Stefan SCHEUERER
  • Patent number: 9650370
    Abstract: This invention relates to novel (Cyano-dimethyl-methyl)-isoxazolesand-[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: May 16, 2017
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Doris Riether, Florian Paul Christian Binder, Henri Doobs, Stephan Georg Mueller, Janet Rachel Nicholson, Achim Sauer